Business
Update on Legal Proceedings
Update on Legal Proceedings.
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 8490A Shield Therapeutics PLC 03 June 2019 \n\nShield Therapeutics plc\n(\"Shield\" or the \"Group\")\n \nUpdate on Legal Proceedings\n \nLondon, UK, 3 June 2019: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces an update on legal proceedings with Teva Pharmaceutical Industries Ltd (TEVA).\n \nFollowing the announcement to shareholders on 14 March 2019, Shield has received notice that TEVA has filed a notice of appeal to the Opposition Division of the European Patent Office's decision on Shield's patent #2 668 175, which covers a \"Process for preparing an iron hydroxypyrone\". No date has been set for the hearing.\n \nShield will continue to robustly defend its intellectual property and believes the Board of Appeal should uphold the first instance decision of the European Patent Office.\n \nShield will provide further updates to shareholders on proceedings as required.\n- Ends -\n \nFor further information please contact:\n \n\n\n\nShield Therapeutics plc\n\n\nwww.shieldtherapeutics.com \n\n\n\n\nCarl Sterritt, Chief Executive Officer\n\n\n+44 (0)20 7186 8500\n\n\n\n\nTim Watts, Chief Financial Officer\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNominated Advisor and Joint Broker\n\n\n\n\n\n\n\nPeel Hunt LLP\n\n\n\n\n\n\n\nJames Steel/Dr Christopher Golden \n\n\n+44 (0)20 7418 8900\n\n\n\n\n\n\n\n\n\n\n\n\nJoint Broker\n\n\n\n\n\n\n\nfinnCap Ltd\n\n\n+44 (0)20 7220 0500\n\n\n\n\nGeoff Nash /Matt Radley/ Alice Lane \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFinancial PR & IR Advisor\n\n\n\n\n\n\n\nWalbrook PR\n\n\n+44 (0)20 7933 8780 or [email protected]\n\n\n\n\nPaul McManus / Anna Dunphy\n\n\n+44 (0)7980 541 893 / +44 (0)7876 74...